325 related articles for article (PubMed ID: 34078141)
1. Review of the Efficacy and Safety of Lemborexant, a Dual Receptor Orexin Antagonist (DORA), in the Treatment of Adults With Insomnia Disorder.
Waters K
Ann Pharmacother; 2022 Feb; 56(2):213-221. PubMed ID: 34078141
[TBL] [Abstract][Full Text] [Related]
2. Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials.
Moline M; Zammit G; Yardley J; Pinner K; Kumar D; Perdomo C; Cheng JY
Postgrad Med; 2021 Jan; 133(1):71-81. PubMed ID: 33119423
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
McElroy H; O'Leary B; Adena M; Campbell R; Monfared AAT; Meier G
J Manag Care Spec Pharm; 2021 Sep; 27(9):1296-1308. PubMed ID: 34121443
[No Abstract] [Full Text] [Related]
5. Lemborexant, an orexin receptor antagonist sedative-hypnotic: Is it useful for insomnia in psychiatric disorders?
Keks NA; Hope J
Australas Psychiatry; 2022 Aug; 30(4):530-532. PubMed ID: 35491942
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of lemborexant 5 mg versus 10 mg for the treatment of insomnia: a systematic review.
Habiba U; Waseem R; Shaikh TG; Waseem S; Ahmed SH; Asghar MS
Neurol Sci; 2023 May; 44(5):1533-1541. PubMed ID: 36633778
[TBL] [Abstract][Full Text] [Related]
7. [Preclinical and clinical efficacy of orexin receptor antagonist Lemborexant (Dayvigo
Koebisu M; Koyama N; Nishida M; Muramoto K
Nihon Yakurigaku Zasshi; 2021; 156(2):114-119. PubMed ID: 33642529
[TBL] [Abstract][Full Text] [Related]
8. Respiratory Safety of Lemborexant in Healthy Subjects: A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Crossover Study.
Cheng JY; Moline M; Zammit GK; Filippov G; Bsharat M; Hall N
Clin Drug Investig; 2021 May; 41(5):449-457. PubMed ID: 33723806
[TBL] [Abstract][Full Text] [Related]
9. Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder.
Chepke C; Jain R; Rosenberg R; Moline M; Yardley J; Pinner K; Kumar D; Perdomo C; Filippov G; Atkins N; Malhotra M
Postgrad Med; 2022 Apr; 134(3):316-325. PubMed ID: 35254948
[TBL] [Abstract][Full Text] [Related]
10. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.
Murphy P; Moline M; Mayleben D; Rosenberg R; Zammit G; Pinner K; Dhadda S; Hong Q; Giorgi L; Satlin A
J Clin Sleep Med; 2017 Nov; 13(11):1289-1299. PubMed ID: 29065953
[TBL] [Abstract][Full Text] [Related]
11. A Comprehensive Review of Lemborexant to Treat Insomnia.
Fuller MC; Carlson SF; Grant C; Berry V; Ivancich M; Cornett EM; Kaye AM; Viswanath O; Urits I; Shekoohi S; Kaye AD
Psychopharmacol Bull; 2024 Mar; 54(1):43-64. PubMed ID: 38449475
[TBL] [Abstract][Full Text] [Related]
12. Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.
Citrome L; Juday T; Frech F; Atkins N
J Clin Psychiatry; 2021 Jun; 82():. PubMed ID: 34077032
[No Abstract] [Full Text] [Related]
13. Evidence-based insomnia treatment strategy using novel orexin antagonists: A review.
Kishi T; Nishida M; Koebis M; Taninaga T; Muramoto K; Kubota N; Moline M; Sakuma K; Okuya M; Nomura I; Iwata N
Neuropsychopharmacol Rep; 2021 Dec; 41(4):450-458. PubMed ID: 34553844
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder.
Lalovic B; Majid O; Aluri J; Landry I; Moline M; Hussein Z
J Clin Pharmacol; 2020 Dec; 60(12):1642-1654. PubMed ID: 32666570
[TBL] [Abstract][Full Text] [Related]
15. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
[TBL] [Abstract][Full Text] [Related]
16. Evaluating lemborexant for the treatment of insomnia.
Zammit G; Krystal A
Expert Opin Pharmacother; 2021 Jul; 22(10):1235-1243. PubMed ID: 33711243
[TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial.
Yardley J; Kärppä M; Inoue Y; Pinner K; Perdomo C; Ishikawa K; Filippov G; Kubota N; Moline M
Sleep Med; 2021 Apr; 80():333-342. PubMed ID: 33636648
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the treatment effectiveness between lemborexant and zolpidem tartrate extended-release for insomnia disorder subtypes defined based on polysomnographic findings.
Inoue Y; Nishida M; Kubota N; Koebis M; Taninaga T; Muramoto K; Ishikawa K; Moline M
J Clin Sleep Med; 2023 Mar; 19(3):519-528. PubMed ID: 36472134
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.
Kärppä M; Yardley J; Pinner K; Filippov G; Zammit G; Moline M; Perdomo C; Inoue Y; Ishikawa K; Kubota N
Sleep; 2020 Sep; 43(9):. PubMed ID: 32585700
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder.
Arnold V; Ancoli-Israel S; Dang-Vu TT; Mishima K; Pinner K; Malhotra M; Moline M
Neurol Ther; 2024 May; ():. PubMed ID: 38748321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
